☆ 4.7 Article

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure

PHARMACEUTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

Shazia Nakhoda et al.

Summary: Bruton tyrosine kinase inhibitors (BTKi) have had a significant impact on the treatment of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma. However, resistance to BTKi remains a challenge, and this review article provides an update on the key clinical data, mechanisms of resistance, and ongoing clinical investigations in CLL, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy

Lindsey E. Roeker et al.

Summary: The review examines the literature supporting treatment options for patients with CLL in both front-line and relapsed/refractory settings. Novel-agent-based approaches have shown survival benefit in the front-line setting, while in the relapsed/refractory setting, BTK inhibitors, venetoclax-based therapy, and PI3K inhibitors have demonstrated survival benefit over chemoimmunotherapy regimens. The role of chemoimmunotherapy in managing CLL has diminished with the availability of effective novel agents and ongoing development of new therapies.

DRUGS (2022)

添加到收藏夹

Review Oncology

Real-world management of targeted therapies in chronic lymphocytic leukemia

Taylor M. Weis et al.

Summary: The advent of novel targeted therapies has dramatically changed the treatment paradigm for chronic lymphocytic leukemia, but resistance mutations and suboptimal outcomes still pose challenges for certain high-risk patients. Additionally, these therapies are associated with drug interactions and unique adverse effects, which can be challenging to manage.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

添加到收藏夹

Review Medicine, General & Internal

Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Ewa Robak et al.

Summary: The use of Bruton's tyrosine kinase (BTK) inhibitors has revolutionized the treatment of patients with B-cell lymphoid malignancies. These inhibitors have also shown promising results in immune-mediated diseases. This review article provides a comprehensive overview of the preclinical and clinical evidence supporting the role of BTK inhibitors in various autoimmune, allergic, and inflammatory conditions.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Oncology

The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030

Mengbao Du et al.

Summary: Leukemia is a common malignancy that has four main subtypes and the global incidence, mortality, and DALY rates of leukemia are decreasing overall, but increasing in high SDI regions. Males bear a heavier burden of leukemia and different subtypes have different impacts on different age groups. Smoking remains the most significant risk factor associated with leukemia and measures to reduce smoking and obesity are needed for leukemia prevention.

JOURNAL OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam et al.

Summary: Zanubrutinib demonstrates superior effectiveness and acceptable safety as frontline therapy for untreated CLL and SLL compared to bendamustine-rituximab.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Immunology

Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)

Maggie Czarnogorski et al.

Summary: This study evaluated the implementation of long-acting cabotegravir + rilpivirine in diverse healthcare settings in the US. The results showed high acceptability, appropriateness, and feasibility of the treatment regimen among healthcare providers. The study also identified strategies for successful implementation and structural changes needed.

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2022)

添加到收藏夹

Meeting Abstract Hematology

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Alessandra Tedeschi et al.

BLOOD (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia

Stefano Molica et al.

Summary: Venetoclax has revolutionized the treatment paradigm of CLL by providing a time-limited, chemo-free therapy option, especially when used in combination with other targeted agents. However, further research is needed to address unanswered questions such as the timing and threshold of MRD evaluation for therapy discontinuation.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Oncology

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Susan M. O'Brien et al.

Summary: BTK inhibitors, such as ibrutinib and acalabrutinib, have been approved for the treatment of B cell malignancies, but have different adverse event profiles and indications. Acalabrutinib, as a second-generation BTK inhibitor, is associated with fewer cases of atrial fibrillation and mainly grade 1-2 headaches compared to ibrutinib. Zanubrutinib, a next-generation BTK inhibitor, is currently approved for MCL treatment but under investigation for CLL.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Crosstalk between Noxa, Bcl-2, and ceramide in mediating p53-dependent apoptosis in Molt-4 human T-cell leukemia

Hadile Kobeissy et al.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story

Arian Emami Riedmaier et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2018)

添加到收藏夹

Article Immunology

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma

John C. Kraft et al.

AIDS (2017)

添加到收藏夹

Article Biology

Evolutionary dynamics of cancer in response to targeted combination therapy

Ivana Bozic et al.

ELIFE (2013)

添加到收藏夹

Article Hematology

Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells:: a cDNA array study

H Savli et al.

BRITISH JOURNAL OF HAEMATOLOGY (2002)

添加到收藏夹

Article Plant Sciences

Inhibition of telomerase activity and bcl-2 expression in berbamine-induced apoptosis in HL-60 cells

ZN Ji et al.

PLANTA MEDICA (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.